ʻO ka lāʻau lapaʻau Johnson & Johnson a me kona pōʻino

ʻO ka lāʻau lapaʻau Johnson & Johnson a me kona pōʻino

Ke hoʻomau nei ka nūhou e pili ana i ka maʻi maʻi ʻo Johnson & Johnson e kūʻē i ka maʻi ʻo Corona, ʻoiai ua hoʻolaha ka mea hoʻoponopono lāʻau lapaʻau ma ʻEulopa ua hoʻohui ia i kahi maʻi neurological laʻa i kapa ʻia ʻo "Guillain-Barré syndrome" ma ke ʻano he hopena ʻaoʻao i ke kano.

I nehinei, Poaha, ua ʻōlelo ka European Union Medicines Control Authority ua loiloi ia i ka ʻikepili i loaʻa, me ka ʻike ʻana ua hoʻoholo ke Kōmike Palekana he pilina ma waena o ka maʻi a me Guillain-Barré syndrome.

Ma Iulai 13, ua ʻōlelo ka US Food and Drug Administration (FDA) i ka piʻi nui ʻana o ka maʻi Guillain-Barré i ka poʻe i loaʻa i ka maʻi kano Johnson & Johnson.

Ua hoʻohui pū ʻia he 100 poʻe i hoʻomohala i ka maʻi ma kahi o 12.5 miliona mau kānaka i loaʻa i kēia kano hoʻokahi.

Ua wehewehe ʻo ia i kēlā manawa mai kēia mau maʻi he 95, ua make kekahi a he XNUMX i mālama ʻia i ka haukapila no ka nui o ko lākou maʻi.

Ma ka hoʻohālikelike ʻana, ua ʻōlelo ʻo Johnson & Johnson i kahi ʻōlelo "he haʻahaʻa loa ka manawa o kēia hanana, a ʻoi aku ka nui o nā hihia i hōʻike ʻia ma mua o ka helu kumu no ka lehulehu ma kahi palena liʻiliʻi."

ʻO ka maʻi Guillain-Barré kahi maʻi o nā aʻalolo āpau e hoʻonāwaliwali mālie a hoʻopale paha iā lākou.

Hoʻomaka pinepine ka lolo ma nā wāwae a i kekahi manawa piʻi i nā ʻiʻo hanu a laila ma nā aʻalolo o ke poʻo a me ka ʻāʻī, a i kēlā me kēia makahiki e pili ana kēia maʻi ma waena o ʻekolu tausani a me ʻeono tausani kānaka ma ʻAmelika Hui Pū ʻIa.

Nā kumuhana ʻē aʻe: 

Pehea ʻoe e hana ai me kāu mea aloha ma hope o ka hoʻi ʻana mai kahi haʻihaʻi?

http://عادات وتقاليد شعوب العالم في الزواج